Roche inks potential $3B multi-target strategic collaboration with Shape Therapeutics
Over the current book year the company from Basel's total revenue could be around 61.84 billion CHF (consensus estimates). This is slightly more than 2021's revenue of 58.32 billion CHF.
Historical revenues and results Roche plus estimates 2021
The analysts expect for 2021 a net profit of 16.96 billion CHF. For this year most of the analysts expect a profit per share of 19.91 CHF. The PE-ratio therefore is 18.46.
Per share the analysts expect a dividend of 9.38 CHF per share. Roche 's dividend yield thus equals 2.55 percent. The average dividend yield of the pharmaceutical companies equals a moderate 1.37 percent.
Recent target prices around 368 CHF
The most recent recommendations for the pharmaceutical company are from JP Morgan, Credit Suisse and Barclays .Roche 's market capitalization is based on the number of outstanding shares around 255.76 billion CHF. 17
At 14.37 the stock trades 0.71 percent lower at 367.6 CHF.Historical stock prices Roche from 2007 till 2021
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.
| About us | Network | Partners |
| Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos |
Analist.nlLinksISIN
|
MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x
|
